Comparative Pharmacology
Head-to-head clinical analysis: ANCEF IN DEXTROSE 5 IN PLASTIC CONTAINER versus CEFOTAXIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF IN DEXTROSE 5 IN PLASTIC CONTAINER versus CEFOTAXIME.
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER vs CEFOTAXIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking. This leads to cell lysis and death, primarily in actively dividing bacteria.
Cefotaxime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
For uncomplicated infections: 1-2 g IV every 8 hours. For severe infections: up to 2 g IV every 4 hours. Administered as an IV infusion over 30-60 minutes.
1-2 g IV every 6-8 hours; maximum 12 g/day. For uncomplicated infections: 1 g IV every 8-12 hours.
None Documented
None Documented
1.8 hours (normal renal function); prolonged to 10-30 hours in severe renal impairment (CrCl <10 mL/min)
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function. In neonates, it is prolonged to 2-4 hours. In severe renal impairment (CrCl <20 mL/min), half-life extends up to 10-15 hours, requiring dose adjustment.
Renal: >80% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <1%
Approximately 80-90% of the dose is excreted unchanged in the urine via glomerular filtration and tubular secretion. About 5-10% is excreted in bile and feces as desacetylcefotaxime, the active metabolite.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic